Trial reportKidney international2015
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Trial report in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02472834 (Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease: A Randomized Trial
Who cites it
36 citing papers in PubMed, 81 citations in OpenAlex.
- Age-associated accumulation of carbamylation-derived products in tissues is independent from the myeloperoxidase pathway in mice.PloS one · 2026Article
- Protein carbamylation is associated with increased mortality and CKD progression in patients with CKD: results from the EQUAL study.Clinical kidney journal · 2025Article
- Carbamylated Albumin, Heart Failure, and Mortality in Patients Undergoing Coronary Angiography.Clinical chemistry · 2025Article
- Homocitrulline Is Associated with Cardiovascular Outcomes in Nondialysis Patients with CKD.Kidney360 · 2025Article
- Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylation.BMC nephrology · 2024Article
- Review
- Review
- Dialysis adequacy and hemoglobin levels predict cerebral atrophy in maintenance-hemodialysis patients.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study.JCI insight · 2022Article
- Arteriovenous Fistulae in Chronic Kidney Disease and the Heart: Physiological, Histological, and Transcriptomic Characterization of a Novel Rat Model.Journal of the American Heart Association · 2022Article
- Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease.Current hypertension reports · 2022Review
- Albumin uptake and processing by the proximal tubule: physiological, pathological, and therapeutic implications.Physiological reviews · 2022Review
- Avenues for post-translational protein modification prevention and therapy.Molecular aspects of medicine · 2022Review
- Review
- Blood Thiol Redox State in Chronic Kidney Disease.International journal of molecular sciences · 2022Review
- Urea levels and cardiovascular disease in patients with chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?International journal of molecular sciences · 2022Review
- Review
- Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease.Drugs in R&D · 2021Article
- Phage-Display-Derived Peptide Specific to Carbamylated Protein.ACS omega · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Serum carbamylated albumin (C-Alb) levels are associated with excess mortality in patients with diabetic end-stage renal disease. To gain insight into the pathophysiology of carbamylation, we determined associations between C-Alb and causes of death in patients on chronic hemodialysis. The Die Deutsche Diabetes Dialyse Studie (4D study) was a randomized controlled trial testing the effects of atorvastatin on survival in diabetic patients on dialysis during a median follow-up of 4 years. We stratified 1161 patients by C-Alb to see whether differences in carbamylation altered the effects of atorvastatin on survival. Baseline C-Alb significantly correlated with serum cardiac stress markers troponin T and N-terminal pro-B-type-natriuretic peptide and was associated with a history of heart failure and arrhythmia. C-Alb was strongly associated with 1-year adjusted risk of cardiovascular mortality, sudden cardiac death, and the 4-year risk of death from congestive heart failure (hazard ratios of 3.06, 3.78, and 4.64, respectively) but not with myocardial infarction or stroke. Patients with low C-Alb, treated with atorvastatin, experienced a significant improvement in their 4-year survival (hazard ratio 0.692). High C-Alb levels are associated with ongoing cardiac damage, risk of congestive heart failure, and sudden cardiac death. Thus, carbamylation and uremic cardiomyopathy are associated in patients with diabetes mellitus and kidney disease. In addition, statins were specifically beneficial to hemodialysis patients with low C-Alb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.